Baystate Wealth Management’s Zymeworks ZYME Stock Holding History

Baystate Wealth Management’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1	Closed	–	–	777
2020 Q3	$0	Buy	+1	New	+$34	﹤0.01%	755

Other funds holding ZYME

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Baystate Wealth Management's ZYME Position: Q4 2020 in Review

Baystate Wealth Management sold out of Zymeworks (ZYME) in Q4 2020, closing a stake of 1 share.

Baystate Wealth Management first reported a position in ZYME in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 138 funds tracked by Wall St. Rank hold ZYME as of Q4 2020.

Baystate Wealth Management reported no remaining Zymeworks position as of Q4 2020 after selling out during the quarter.
Baystate Wealth Management sold 1 Zymeworks share in Q4 2020.
Baystate Wealth Management first reported a position in Zymeworks in Q3 2020 and held it in 1 quarter.
Baystate Wealth Management's Zymeworks position peaked at $0 in Q3 2020.
138 funds tracked by Wall St. Rank held Zymeworks as of Q4 2020.

Based on Baystate Wealth Management's 13F filing for Q4 2020, filed 15 Jan 2021.